Northern, WI 06/20/2013 (usastockreport) – The share prices of Keryx Biopharmaceuticals (NASDAQ:KERX) had been traded in the price range of $8.02 and $8.50 per share on Wednesday. The company’s share price had had gradually increased by 7.57 percent, with a closing price of $8.24 per share. The share price of does not made a change in the 52 week low value $1.68 per share and 52 week high value $9.98 per share.
Keryx Biopharmaceuticals (NASDAQ:KERX) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of cancer and renal disease.
J.P Morgan, an analyst initiating coverage of Keryx Biopharmaceuticals (NASDAQ:KERX) based on the potential of Zerenex, its first-in class, oral drug candidate for the treatment of hyperphosphatemia (elevated serum of phosphorus) in a dialysis patients. Its ability to also help to treat anemia, the advantage of pharmacoeconomic advantages Zerenex could drive rapid uptake in the price sensitive end stage renal disease (ESRD) market. Thus the stock initiated with the overweight rating at J.P.Morgan.
Keryx Biopharmaceuticals (NASDAQ:KERX) generated an income of $-18.30 million in the last twelve months and sales of $ 7 million. KERX return on equity ratio is recorded as -47.40 percent and its return on asset is -37.80 percent. Last week KERX presented its Zerenex, pivotal phase-III clinical study, at the World Congress of Nephrology. The new data for this phosphate – binder continues supporting the game hanging treatment. It has a Phosphate binding as well as significant anemia benefits and will be highly beneficial for dialysis patients.
The market capitalization value is about 673.36 million and institutional investors share’s percent is about 66. Dynavax has been having a trading volume as 9.27 million and the average volume as 2.35 million per day on Wednesday. The company presently holds 81.72 million shares outstanding in the market.